Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia

[1]  R. Vandenberghe,et al.  Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein , 2019, Acta Neuropathologica.

[2]  D. Dickson,et al.  The neuropathological diagnosis of Alzheimer’s disease , 2019, Molecular Neurodegeneration.

[3]  Keith A. Johnson,et al.  Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease , 2019, JAMA neurology.

[4]  Si Eun Kim,et al.  Clinical significance of amyloid β positivity in patients with probable cerebral amyloid angiopathy markers , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  C. Jack,et al.  Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology , 2018, Alzheimer's & Dementia.

[6]  T. Beach,et al.  Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition , 2018, Acta Neuropathologica.

[7]  C. V. von Arnim,et al.  Modified amyloid variants in pathological subgroups of β‐amyloidosis , 2018, Annals of clinical and translational neurology.

[8]  Keith A. Johnson,et al.  PET staging of amyloidosis using striatum , 2018, Alzheimer's & Dementia.

[9]  J. Baron,et al.  Amyloid-PET in sporadic cerebral amyloid angiopathy , 2017, Neurology.

[10]  A. Fleisher,et al.  Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease , 2017, Alzheimer's & dementia.

[11]  Christopher C Rowe,et al.  Biochemically-defined pools of amyloid-&bgr; in sporadic Alzheimer’s disease: correlation with amyloid PET , 2017, Brain : a journal of neurology.

[12]  J. Attems,et al.  Interactions of pathological proteins in neurodegenerative diseases , 2017, Acta Neuropathologica.

[13]  W. Klunk,et al.  Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection , 2016, Acta neuropathologica communications.

[14]  Mehriar Amininasab,et al.  Phosphorylation modifies the molecular stability of β-amyloid deposits , 2016, Nature Communications.

[15]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[16]  J. Trojanowski,et al.  Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology , 2016, Acta Neuropathologica.

[17]  Young T. Hong,et al.  Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value? , 2015, PloS one.

[18]  Kerstin Heurling,et al.  [18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β pathology , 2015, Alzheimer's & Dementia.

[19]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[20]  S. Love,et al.  Investigation of Aβ phosphorylated at serine 8 (pAβ) in Alzheimer's disease, dementia with Lewy bodies and vascular dementia , 2015, Neuropathology and applied neurobiology.

[21]  Clifford R. Jack,et al.  Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[22]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[23]  H. Braak,et al.  PART is part of Alzheimer disease , 2015, Acta Neuropathologica.

[24]  Thomas Arzberger,et al.  Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies , 2015, Journal of Neural Transmission.

[25]  Janna H. Neltner,et al.  Quantitative neuropathological assessment to investigate cerebral multi-morbidity , 2014, Alzheimer's Research & Therapy.

[26]  K. Jellinger,et al.  The overlap between vascular disease and Alzheimer’s disease - lessons from pathology , 2014, BMC Medicine.

[27]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[28]  Lennart Thurfjell,et al.  Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.

[29]  Young T. Hong,et al.  Diagnostic Utility of Amyloid PET in Cerebral Amyloid Angiopathy-Related Symptomatic Intracerebral Hemorrhage , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  L. Thurfjell,et al.  Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  C. V. von Arnim,et al.  Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. , 2014, Brain : a journal of neurology.

[32]  S. Hatashita,et al.  [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  J. Attems,et al.  Pathology of clinical and preclinical Alzheimer’s disease , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[34]  J. Trojanowski,et al.  Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. , 2013, Brain : a journal of neurology.

[35]  H. Chertkow,et al.  Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease? , 2013, JAMA neurology.

[36]  K. Blennow,et al.  Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid , 2013, Acta Neuropathologica.

[37]  T. Bayer,et al.  Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer’s disease , 2013, Acta Neuropathologica.

[38]  M. Staufenbiel,et al.  Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice , 2012, Neurobiology of Aging.

[39]  John L. Robinson,et al.  Neuropathologic substrates of Parkinson disease dementia , 2012, Annals of neurology.

[40]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[41]  M. Fändrich,et al.  High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain , 2012, Journal of cellular and molecular medicine.

[42]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[43]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[44]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[45]  Keith A. Johnson,et al.  Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy , 2010, Annals of neurology.

[46]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[47]  D. Selkoe,et al.  The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. , 2010, Brain : a journal of neurology.

[48]  G. Hause,et al.  Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. , 2009, Biochemistry.

[49]  S. Al-Sarraj,et al.  Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. , 2009, Acta neuropathologica.

[50]  H. Braak,et al.  Parenchymal and vascular Aβ-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease , 2008, Journal of cellular and molecular medicine.

[51]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[52]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[53]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[54]  O. Wiestler,et al.  Vascular Pathology in Alzheimer Disease: Correlation of Cerebral Amyloid Angiopathy and Arteriosclerosis/Lipohyalinosis with Cognitive Decline , 2003, Journal of neuropathology and experimental neurology.

[55]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[56]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[57]  D. Dickson,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[58]  H. Braak,et al.  Sequence of Aβ‐Protein Deposition in the Human Medial Temporal Lobe , 2000 .

[59]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[60]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[61]  J. Trojanowski,et al.  The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging , 1999, Experimental Neurology.

[62]  M. Ball,et al.  Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.

[63]  D. Selkoe,et al.  Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation , 1996, Neurobiology of Disease.

[64]  D. Mann,et al.  Dominant and differential deposition of distinct β-amyloid peptide species, Aβ N3(pE), in senile plaques , 1995, Neuron.

[65]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[66]  E. Masliah,et al.  Plaque‐Only Alzheimer Disease is Usually the Lewy Body Variant, and Vice Versa , 1993, Journal of neuropathology and experimental neurology.

[67]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[68]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[69]  J. Vonsattel,et al.  Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study , 1991, Annals of neurology.

[70]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[71]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[72]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[73]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[74]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[75]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[76]  C. Buckley,et al.  Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology. , 2016, Journal of Alzheimer's disease : JAD.

[77]  M. Fändrich,et al.  Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease , 2014, Acta Neuropathologica.

[78]  D. Bennett,et al.  AHA / ASA Scientific Statement Vascular Contributions to Cognitive Impairment and Dementia , 2011 .

[79]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[80]  K. Jellinger,et al.  Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: a rare subtype in very old subjects , 2004, Acta Neuropathologica.

[81]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[82]  H. Braak,et al.  Sequence of Abeta-protein deposition in the human medial temporal lobe. , 2000, Journal of neuropathology and experimental neurology.

[83]  L. Lue,et al.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.

[84]  D. Thal,et al.  Stage-correlated distribution of type 1 and 2 dystrophic neurites in cortical and hippocampal plaques in Alzheimer's disease. , 1998, Journal fur Hirnforschung.

[85]  D. Mann,et al.  Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. , 1995, Neuron.

[86]  T. Iwatsubo,et al.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.